Advertisement
Advertisement
GH
Guardant Health, Inc. Common Stock
164.96
USDSponsored
-2.25
-1.35%
Aug 11, 15:59 UTC -4
Closed
After-Market
167.00
+2.04
+1.24%
GH Earnings Reports
Positive Surprise Ratio
GH beat 14 of 32 last estimates.
44%
Next Report
Date of Next Report
Oct 27, 2026
Estimate for Q3 26 (Revenue/ EPS)
$360.51M
/-$0.31
Implied change from Q2 26 (Revenue/ EPS)
+4.50%
/-26.19%
Implied change from Q3 25 (Revenue/ EPS)
+35.94%
/-58.11%
Guardant Health, Inc. Common Stock earnings per share and revenue
On Jul 30, 2026, GH reported earnings of -0.42 USD per share (EPS) for Q2 26, missing the estimate of -0.41 USD, resulting in a -0.02% surprise. Revenue reached 344.98 million, compared to an expected 323.65 million, with a 6.59% difference. The market reacted with a +6.33% price change (close before vs. close after earnings).
Looking ahead to Q3 26, 23 analysts forecast an EPS of -0.31 USD, with revenue projected to reach 360.51 million USD, implying an decrease of -26.19% EPS, and increase of 4.50% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Axsome Therapeutics, Inc
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.86
Actual
-$0.99
Surprise
-14.90%
Legend Biotech Corporation - ADR
Report Date
Aug 11, 2026 For Q2 26
Estimate
$0.07
Actual
$0.09
Surprise
+17.80%
Bicara Therapeutics Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.84
Actual
-$0.82
Surprise
+3.18%
Olema Pharmaceuticals, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.55
Actual
-$0.61
Surprise
-9.83%
Autolus Therapeutics plc - ADR
Report Date
Aug 11, 2026 For Q2 26
Estimate
-$0.22
Actual
-$0.15
Surprise
+31.82%
Fennec Pharmaceuticals Inc. Common Stock
Report Date
Aug 11, 2026 For Q2 26
Estimate
$0.01
Actual
$0.05
Surprise
+400.00%
Enanta Pharmaceuticals, Inc
Report Date
Aug 10, 2026 For Q3 26
Estimate
-$0.52
Actual
-$0.67
Surprise
-28.80%
Palisade Bio, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.05
Actual
-$0.05
Surprise
+6.19%
DiaMedica Therapeutics Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.20
Actual
-$0.19
Surprise
+6.86%
TELA Bio, Inc. Common Stock
Report Date
Aug 10, 2026 For Q2 26
Estimate
-$0.18
Actual
-$0.20
Surprise
-10.01%
FAQ
What were Guardant Health, Inc. Common Stock's earnings and revenue for the latest quarter Q2 2026?
For Q2 2026, Guardant Health, Inc. Common Stock reported EPS of -$0.42, missing estimates by -0.02%, and revenue of $344.98M, 6.59% above expectations.
How did the market react to Guardant Health, Inc. Common Stock's Q2 2026 earnings?
The stock price moved up 6.33%, changed from $152.35 before the earnings release to $161.99 the day after.
When is Guardant Health, Inc. Common Stock expected to report next?
The next earning report is scheduled for Oct 27, 2026.
What are the forecasts for Guardant Health, Inc. Common Stock's next earnings report?
Based on 23
analysts, Guardant Health, Inc. Common Stock is expected to report EPS of -$0.31 and revenue of $360.51M for Q3 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement